Kamada is a plasma-derived biopharmaceutical company focused on orphan indications, with an existing marketed product portfolio and a late-stage product pipeline. Co.'s main products are produced using its main technologies and know-how for the separation and purification of proteins derived from human plasma. Co. operates in two segments: Proprietary Products, in which it develops and manufactures plasma-derived therapeutics and has a product line consisting of six pharmaceutical products that it markets in various countries; and Distribution, in which it utilizes its capability and presence in the Israeli market by distributing drugs manufactured by third-parties for use in Israel. The KMDA stock yearly return is shown above.
The yearly return on the KMDA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KMDA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|